cells, a phenomenon called syncytium formation that is 4,3 hydrophobic repeat regions within gp41 form a helireadily observed in cultured cells and may be responsical trimer of antiparallel dimers (Lu et al., 1995) . Crystalble for some of the cytopathic effects of advanced HIV lographic analysis confirmed that this gp41 core is a infection. Here we review recent insights in HIV envelope six-helix bundle in which the N and C helices are arprotein structure and function and present our current ranged into three hairpins (Figures 1B and 1C) (Chan et understanding of the entry process. We also review how al. , 1997; Weissenhorn et al., 1997) . The N peptides form these findings lead to new approaches for inhibiting HIV three central helices arranged in a trimeric coiled coil. entry and may provide insights into the design of better The C peptides form three outer helices that pack in an HIV vaccines.
antiparallel manner into highly conserved, hydrophobic The HIV-1 envelope protein complex is initially progrooves on the surface of this coiled coil ( Figure 1D ). duced as the precursor gp160, which is extensively glyThis structure likely represents the fusion-active conforcosylated and proteolytically cleaved into two subunits mation of gp41 (see discussion in Chan et al., 1997) , and by a cellular convertase (Luciw, 1996) . The resulting resembles the proposed fusion-active conformations of surface subunit (gp120) and transmembrane subunit the transmembrane envelope proteins from influenza (gp41) remain noncovalently associated and oligomervirus and Moloney murine leukemia virus. ize, most likely as trimers, on the surface of the virion.
Fusion Mechanism gp120 binds to CD4 and a coreceptor (a seven-transAny model for HIV entry must account for the remarkable membrane protein of the chemokine receptor family), observation that synthetic C peptides inhibit HIV infecwhich are present on susceptible cells such as T lymtion and syncytia formation at nanomolar concentraphocytes and macrophages. Subsequently, gp41 undertions (Jiang et al., 1993; Wild et al., 1994) . Preincubation goes conformational changes that mediate fusion of the of virus with C peptide, followed by its removal, does viral membrane with the target cell membrane. HIV entry not block HIV entry; this feature suggests that these is therefore a complex process involving multiple protein peptides do not act on the native conformation of gp41. interactions, each of which is a potential target for the Based on the structural features of the fusion-active development of antiviral compounds. gp41 core, these peptide inhibitors likely work by bindgp41 Structure ing to the trimeric coiled coil of gp41, thereby acting The gp41 molecule is a transmembrane protein with through a dominant-negative mechanism (Lu et al., several important features within its ectodomain (Figure 1995; Chan et al., 1997; Weissenhorn et al., 1997) . 1A). First, the amino terminus of gp41, created by pro-A simple dominant-negative model, however, fails to teolytic cleavage of the gp160 precursor, contains a explain adequately one puzzling feature of C peptide hydrophobic, glycine-rich "fusion" peptide that is esseninhibition: How can C peptides act at such low concential for membrane fusion. Second, there are two regions trations, given that the N and C peptide regions are with a 4,3 hydrophobic (heptad) repeat, a sequence mowithin a single gp41 molecule? That is, how can the C tif characteristic of coiled coils. Synthetic peptides (see peptides so effectively inhibit an intramolecular associabelow) derived from these two regions are termed N tion reaction, in which the two regions of gp41 are pres-(amino-terminal) and C (carboxy-terminal) peptides. Beent in a high effective concentration? It seems likely that tween these two heptad repeat regions is a loop region the solution to this puzzle is that C peptides must bind containing two cysteines.
to gp41 prior to formation of the six-helix complex be-A large number of studies support the notion that the cause, once this gp41 core is assembled, it is extremely envelope complex exists in at least two major conformastable (the melting temperature of the gp41 core is in tions (see references in Chan et al., 1997) . The native, excess of 90ЊC) and is unlikely to be disrupted by exogeor nonfusogenic, conformation exists on the surface nous peptides. These observations suggest the exisof free virions after budding from infected cells. Upon tence of a transiently populated, third state of gp41. C binding of gp120 to target cell receptors, gp41 undergoes a conformational change to a fusion-active state.
peptides act at this intermediate stage, after the native state has undergone a conformational transition but beand is then relatively stable, with a lifetime of many minutes. Video microscopy and the fluorescent dye bisfore formation of the hairpin structure. In this "prehairpin" intermediate, the N and C peptide regions are not ANS have been used to monitor the kinetics of receptoractivated conformational changes (Jones et al., 1998) . associated, allowing synthetic C peptides to bind to the N peptide region of gp41 and inhibit transition to the These studies indicate that conformational changes are initiated within 1-4 min of receptor binding and are comfusion-active conformation (Figure 2) .
The prehairpin intermediate appears to be induced plete within 20 min, well before any evidence of lipid mixing. Significantly, C peptides retain much of their rapidly upon interaction of gp120 with cellular receptors In the native state of the trimeric gp120 (green)/gp41 (blue/gray shading) complex, the fusion peptide (not shown) is buried. Upon interaction of gp120 with cellular receptors, the envelope complex undergoes a conformational change to the prehairpin intermediate, in which the fusion peptide (red lines) is inserted into the target membrane and the N peptide region (gray) is a trimeric coiled coil. The C peptide region (blue) has not yet associated with the N peptide coiled coil because of a kinetic block due to association with either another portion of gp41, or more likely, gp120. This intermediate is relatively long-lived (many minutes) and is vulnerable to C peptide inhibition (bottom). The prehairpin intermediate resolves to the fusion-active hairpin structure when the C peptide region binds to the N peptide coiled coil and adopts a helical conformation. This rearrangement results in membrane apposition. The interactions necessary for fusion are unknown (as indicated by "?"), but may involve aggregation of gp41 trimers to form fusion pores. After fusion is completed, the fusion peptide and the transmembrane segment (purple lines) of gp41 lie within the same membrane. The steps at which various HIV entry inhibitors act are shown. inhibitory activity against membrane fusion when added more difficult to select for viruses resistant to T649 (Figure 1A) , a C peptide that contains the cavity binding after these rapid conformational changes (Munoz-Barroso et al., 1998).
region (Rimsky et al., 1998) . Steps toward the development of more potent versions of C peptides have begun Taken together, these observations suggest the following model for gp41-mediated membrane fusion (Fig-(Judice et al., 1997) . Targeting Cellular Receptors ure 2) (for related models, see Hughson, 1997; Weissenhorn et al., 1997; Furuta et al., 1998) . In free virions, Early work targeting cellular receptors focused on using soluble versions of CD4 as HIV entry inhibitors. This gp41 exists in a native, nonfusogenic conformation in which the fusion peptides are buried within the envelope approach, while effective against laboratory-adapted HIV strains in vitro, has proved ineffective on primary complex. This gp41 structure is stabilized by its interactions with gp120. When gp120 binds to cell-surface CD4
HIV isolates. The identification of the chemokine receptors as essential cofactors has led to new targets for and a chemokine receptor, a conformational change occurs in gp120 that alters gp120-gp41 interactions.
inhibition of viral entry. The chemokines themselves, or variants thereof, form a potent class of inhibitors This perturbation of the gp120-gp41 interaction triggers gp41 to undergo its transition to the prehairpin interme-(reviewed in Littman, 1998). HIV strains that use the CCR5 coreceptors are blocked by the CCR5 ligands diate. These changes in gp41 include exposure of the fusion peptide and its insertion into the target mem-RANTES, MIP-1␣, and MIP-1␤; likewise, strains that use the CXCR4 coreceptor are blocked by the CXCR4 ligand brane. We imagine that the prehairpin intermediate penetrates the target membrane with its fusion peptide, SDF (stromal-derived factor). These factors appear to work through two mechanisms. First, they competitively which lies on top of the N peptide coiled coil. The C peptide region is not associated with this coiled coil, block interaction of gp120 with the chemokine receptors. Second, they down-regulate chemokine receptor perhaps because it is constrained by an interaction with another region of gp41, or more likely, gp120. This preexpression in the target cells, thereby limiting the number of HIV entry points. hairpin intermediate represents the vulnerable target of C peptide inhibition. Consistent with this view, the C Progress has already been made in identifying smallmolecule inhibitors of the chemokine receptors (see peptide DP178 binds to gp41 only after interaction of the envelope complex with cellular receptors (Furuta et references in Littman, 1998) . Two such compounds, ALX40-4C and T22, are short, positively charged pepal., 1998).
The resolution of this intermediate to the six-helix tides. A third, called AMD3100, is a bicyclam compound. All three of these compounds inhibit entry of HIV strains complex may be slow because the constraints holding the C peptide region are slow to dissociate. Moreover, that utilize CXCR4 as a coreceptor and likely work by binding directly to CXCR4, thereby blocking its interacthere are topological constraints that prevent a simple, symmetric transition from the prehairpin intermediate tion with gp120. Eliciting Neutralizing Antibodies to the six-helix structure. Once these constraints are overcome, association of the C peptide region with the The need for an HIV vaccine remains urgent, and many past efforts have focused on eliciting a neutralizing anti-N peptide coiled coil leads to formation of the fusionactive hairpin structure and the local apposition of viral body response against the envelope complex (reviewed in Burton, 1997; Haynes, 1996) . Passive transfer of high and cellular membranes. How membrane apposition leads to complete fusion is unclear but may involve levels of neutralizing monoclonal antibodies has been shown in animal models to protect against a virus chalclustering of envelope protein trimers to form fusion pores. After fusion is complete, the fusion peptide and lenge. The ability of live-attenuated SIV vaccines to protect macaques from a challenge virus in the absence of the transmembrane segment of gp41 lie in the same membrane (Figure 2 ). Recent work suggests that, in a a strong neutralizing antibody response suggests that other mechanisms, including cell-mediated immunity, manner analogous to viral entry, fusion between cellular membranes mediated by t-SNARE and v-SNARE protein are capable of providing protection. The importance of generating T cell responses to HIV is well recognized, complexes also involves helical structures to appose two membranes for fusion (Weber et al., 1998) .
but we restrict our discussion to approaches for eliciting neutralizing antibodies to HIV.
gp41-Derived Peptides Are Potent Fusion Inhibitors
Human vaccine trials using monomeric gp120 as an immunogen have yielded disappointing results (VanCott In the gp41 core, each of the outer C helices binds along a conserved groove on the surface of the central coiled et al., 1995; Haynes, 1996; Bolognesi and Matthews, 1998; Connor et al., 1998) . Individuals immunized with coil. The broad inhibitory activity of C peptides against diverse HIV isolates is explained by the highly conserved monomeric gp120 show low levels of neutralizing antibodies that are effective only against the HIV strains to nature of the hydrophobic groove to which these peptides bind. Toward the bottom of the groove is a deep which they were immunized, and not to primary isolates. Preparations of gp120 used in early vaccination trials cavity that is filled by three hydrophobic residues from the C helix ( Figure 1D ). This pocket is potentially a good were derived from laboratory-adapted HIV strains, which are now known to be substantially more sensitive to target for inhibiting HIV invasion (Chan et al., 1997) , although peptides lacking the cavity-occupying residues neutralization than primary clinical isolates (Mascola et al., 1996) . Perhaps most telling, antibody responses in (e.g., DP-178; see Figure 1A ) can still be potent inhibitors. As may be expected, mutant viruses that escape gp120-vaccinated individuals are often directed against linear epitopes exposed on denatured gp120 but not DP178 inhibition bear mutations in the N peptide region of gp41 (Rimsky et al., 1998 ization state. Since the unprocessed envelope precursor is different from the mature protein, these preparations should be processed to gp120/gp41. However, this maturation-cleavage step presents another problem: gp120 is readily "shed" from gp41. Shedding was also a problem with early whole-killed (inactivated) HIV preparations, and methods for cross-linking envelope protein subunits may prove crucial. Similar considerations apply to pseudotyped-virus preparations, such as the canarypox virus vaccine candidate (see Bolognesi and Matthews, 1998 ). Finally, it remains possible that, even with optimized envelope protein preparations, these vaccines will generate only strain-restricted responses because broadly neutralizing epitopes are rare and poorly immunogenic. In this case, it may be necessary to resort to cocktails of envelope proteins from selected primary isolates. It seems almost certain, however, that the challenge of eliciting broadly neutralizing antibodies to HIV will require close attention to issues of protein structure and conformation in vaccine candidates. 
